Partner Headlines - GSK

  1. Alphabet-Glaxo Joint Venture Targets 'Bioelectronics'

    Investors Business Daily
  2. Veeva Is Key Partner In Big Pharma's Race Against The Clock

    Investors Business Daily
  3. Stock Futures Up, Gaining Strength; Apple Hauls Techs Higher

    Investors Business Daily
  4. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  5. Getting to Know VBI Vaccines

    GuruFocus
  6. Brandes Makes a Variety of Reductions in 4th Quarter

    GuruFocus
  7. Stock Futures Up As Oil Behaves; Syngenta Up On ChemChina Deal

    IBD
  8. EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, ...

    Benzinga
  9. Benzinga's M&A Chatter for Thursday January 28, 2015

    Benzinga
  10. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  11. Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

    GuruFocus
  12. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  13. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  14. Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  15. Cisco Systems, Microsoft and Intel Bring High Dividend Yields ...

    GuruFocus
  16. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  17. High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox ...

    GuruFocus
  18. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  19. John Rogers' Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  20. 3 Global Investment Ideas From Gurus

    GuruFocus
  21. Relypsa Stock Jumps On Buyout Rumors

    IBD
  22. Skin Disease Drug Costs Jump

    IBD
  23. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD
  24. Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline

    GuruFocus
  25. 3 Investment Ideas of Ariel Investment's Rupal Bhansali

    GuruFocus
  26. Pfizer to Create a New Pharmaceutical Colossus

    GuruFocus
  27. GlaxoSmithKline

    IBD
  28. Gilead Beats Q3 Estimates As HIV Franchise Shines

    IBD
  29. ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase ...

    Benzinga
  30. Benzinga's Top Upgrades

    Benzinga
  31. IBM, Schlumberger PTs Lowered; Valeant Downgraded

    IBD
  32. GlaxoSmithKline Has a High (and Dangerous) Dividend Yield

    GuruFocus
  33. Tweedy Browne Global Value Adds to Stake in GlaxoSmithKline

    GuruFocus
  34. Liquidia Technologies And GlaxoSmithKline Advance Existing Collaboration; ...

    Benzinga
  35. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  36. Regulatory Update: GSK and Theravance Announce Intention to File ...

    GuruFocus
  37. Guru Stocks at 52-Week Lows: RDS.A, PTR, UL, BP, GSK

    GuruFocus
  38. Five Prime Therapeutics Announces Initial Data From Ongoing Phase ...

    Benzinga
  39. GSK and Theravance Announce Results From the SUMMIT COPD CV Survival ...

    GuruFocus
  40. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  41. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  42. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  43. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  44. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  45. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  46. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  47. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  48. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  49. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  50. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  51. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  52. Benzinga's Volume Movers

    Benzinga
  53. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  54. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  55. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  56. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  57. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  58. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  59. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  60. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  61. Axovant IPO Best In 20 Years

    IBD
  62. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  63. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  64. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  65. Perrigo buys Glaxo OTC drugs

    IBD
  66. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  67. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  68. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  69. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  70. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  71. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  72. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  73. Glaxo more bullish than Q1

    IBD
  74. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  75. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  76. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  77. GlaxoSmithKline

    IBD
  78. Novartis EPS beats the Street

    IBD
  79. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  80. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  81. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  82. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  83. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  84. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  85. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  86. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  87. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  88. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  89. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  90. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  91. Benzinga's Weekend M&A Chatter

    Benzinga
  92. Gilead Sciences Still has More Upside

    GuruFocus
  93. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  94. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  95. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  96. Isis Pharma To Develop GI Drugs With J&J

    IBD
  97. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  98. Ebola Drug Work Continues

    IBD
  99. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  100. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
Trading Center